Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks

Page 6 of 10

5. Immatics N.V. (NASDAQ:IMTX)

Number of Hedge Fund Holders: 32 

Perceptive Advisors’ Stake: $13.4 million

Immatics N.V. (NASDAQ:IMTX) is a clinical-stage biopharmaceutical company that focuses on the research and development of potential T-cell redirecting immunotherapies for the treatment of cancer in the United States. There are multiple factors, such as strong financial performance, strategic partnerships, and a growing development pipeline, that make this company a good investment opportunity. For instance, as per the report of the third quarter of 2024, total revenue, consisting of revenue from collaboration agreements, was $56.7 million as compared to $6.6 million of the last year. In addition, the research and development investment was $48 million, underscoring a focused commitment to advancing the therapeutic pipeline.

Page 6 of 10